Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Status: Publicly traded
Direct answer
Suzhou Zelgen Biopharmaceuticals Co., Ltd. is publicly traded on SHH under the ticker 688266.SS.
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk...
Can you invest in Suzhou Zelgen Biopharmaceuticals Co., Ltd.?
Yes. Suzhou Zelgen Biopharmaceuticals Co., Ltd. is publicly traded on SHH under the ticker 688266.SS.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Detailed equity research is provided by MarketSnap.